The COVID-19 pandemic has hit a temporary pause button on routine inspections of device firms by the US Food and Drug Administration. But background work on inspections continues, and that includes a new final guidance document offering guidelines on how the agency will conduct device establishment inspections.
The document, which was published 25 June, finalizes a draft guidance issued in March 2019. The FDA Reauthorization Act (FDARA)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?